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OBJECTIVES: We aimed to investigate whether glucocorticoid receptor gene polymorphisms are associated with
clinical and metabolic profiles in patients with polycystic ovary syndrome. Polycystic ovary syndrome is a
complex endocrine disease that affects 5-8% of women and may be associated with metabolic syndrome, which
is a risk factor for cardiovascular disease. Cortisol action and dysregulation account for metabolic syndrome
development in the general population. As glucocorticoid receptor gene (NR3C1) polymorphisms regulate
cortisol sensitivity, we hypothesized that variants of this gene may be involved in the adverse metabolic profiles
of patients with polycystic ovary syndrome.
METHOD: Clinical, metabolic and hormonal profiles were evaluated in 97 patients with polycystic ovary
syndrome who were diagnosed according to the Rotterdam criteria. The alleles of the glucocorticoid gene were
genotyped. Association analyses were performed using the appropriate statistical tests.
RESULTS: Obesity and metabolic syndrome were observed in 42.3% and 26.8% of patients, respectively. Body
mass index was positively correlated with blood pressure, triglyceride, LDL-c, total cholesterol, glucose and
insulin levels as well as HOMA-IR values and inversely correlated with HDL-c and SHBG levels. The BclI and
A3669G variants were found in 24.7% and 13.4% of alleles, respectively. BclI carriers presented a lower
frequency of insulin resistance compared with wild-type subjects.
CONCLUSION: The BclI variant is associated with a lower frequency of insulin resistance in women with
polycystic ovary syndrome. Glucocorticoid gene polymorphism screening during treatment of the syndrome
may be useful for identifying subgroups of at-risk patients who would benefit the most from personalized
treatment.
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& INTRODUCTION
Polycystic ovary syndrome (PCOS) is one of the most
common endocrinopathies in women of reproductive age
(1). The syndrome’s presentation is highly heterogeneous
and is characterized by menstrual dysfunction, hyperan-
drogenism and/or hyperandrogenemia and polycystic
ovary morphology (1). Women with PCOS are frequently
insulin resistant, regardless of the presence of obesity (1),
and have an adverse metabolic profile.
Previous studies have suggested that cortisol dynamics
are dysregulated in PCOS, primarily through increased
hypothalamic-pituitary-adrenal (HPA) axis activity and
enhanced cortisol sensitivity (1). Steroid hormones play a
central role in the regulation of body composition.
Glucocorticoids (GCs) have numerous effects, including
regulation of fat distribution, lipid metabolism and insulin
sensitivity (2); therefore, GC dysregulation may play a role
in several PCOS manifestations.
The glucocorticoid receptor (GR) is crucial for the effects
of GCs, and several GR gene (NR3C1) polymorphisms have
been associated with altered GC sensitivity, suggesting that
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these polymorphisms can modulate the development of
metabolic disorders (2,3). In the general population, several
NR3C1 polymorphisms are associated with differences in
body composition, metabolic parameters and cardiovascu-
lar disease. For example, the BclI NR3C1 polymorphism,
located in intron 2, has been associated with increased GC
sensitivity and an adverse metabolic profile (4-6). Similarly,
the N363S polymorphism was reported to be associated
with enhanced GC sensitivity and was linked to an
increased body mass index (BMI), elevated LDL cholesterol
levels and an increased risk of cardiovascular disease (7-9).
In contrast, the A3669G and ER22/23EK polymorphisms are
associated with decreased GC sensitivity and relative GC
resistance, and GC resistance has been associated with a
favorable metabolic profile and body composition in
addition to a smaller decrease in cortisol levels after the
dexamethasone suppression test (DST) (2). Furthermore,
NR3C1 polymorphisms are associated with the classical
form of 21-hydroxylase deficiency, another hyperandro-
genic condition (10).
Given the influence of GCs on body composition and
metabolic control, we hypothesized that genetic variations
might be linked to PCOS features. Thus, the aim of this
study was to evaluate the influence of NR3C1 polymorph-
isms (BclI, A3669G and ER22/23EK) on the phenotypic
expression of PCOS.
& MATERIALS AND METHODS
The procedures used were in accordance with the
guidelines of the Helsinki Declaration on human experi-
mentation. The study protocol was approved by the Ethics
Committee of the Hospital das Clı´nicas da Universidade de
Sa˜o Paulo, and written informed consent was obtained from
all the women before the start of the study.
Subjects
In total, 97 PCOS patients were selected for this study;
their mean age was 24.9¡5.1 years old. The patients’ mean
BMI was 29.6¡6.9 kg/m2, and their mean waist circumfer-
ence was 90.1¡15.2 cm. All subjects were referred for
evaluation of hirsutism and/or menstrual abnormalities.
Eumenorrhea was defined as the presence of menstrual
cycles between 25 and 34 days. At least two consecutive
cycles with low progesterone levels (,3 ng/mL) were
required for a diagnosis of anovulation. Oligomenorrhea
was defined as the presence of three or more cycles of .35
days in the previous 6 months and amenorrhea due to a lack
of vaginal bleeding for 3 months. Hypermenorrhea was
defined as the presence of vaginal bleeding at intervals of
,21 days.
PCOS diagnosis was performed according to the
Rotterdam Consensus (11). Cushing’s syndrome, late-onset
21-hydroxylase deficiency, thyroid dysfunction, hyperpro-
lactinemia and androgen-secreting tumors were ruled out
using the appropriate tests. None of the women had any
other diseases or had taken any medications for at least 6
months prior to the study.
Abdominal or pelvic ultrasonography was performed on
all subjects. The presence of polycystic ovaries was
established by the presence of 12 or more follicles in each
ovary measuring 2-9 mm in diameter and/or an ovarian
volume greater than 10 mL.
Study protocol
BMI and waist circumference were measured in all
subjects. The presence of hirsutism was quantified using
the modified Ferriman-Gallwey (mFG) score, and the
presence of acne was also evaluated.
All blood samples were collected between 7:30 and 8:30
A.M. after an overnight fast. Blood samples were collected
from days 1-3 of the cycle in women with regular menstrual
cycles. For those patients with menstrual abnormalities,
sampling was performed regardless of the time of the last
menstrual bleeding, and serum progesterone (P) was
assayed to confirm the absence of ovulation at the time of
the assessment.
For the oral glucose tolerance test (OGTT), a basal sample
was obtained for the determination of glucose, insulin,
triglycerides (TGs) and total cholesterol (TC) as well as TC
fractions (LDL-c and HDL-c). A glucose load of 75 g was
then given, and blood was drawn after 30, 60, 90 and 120
minutes for the determination of glucose and insulin levels.
Insulin sensitivity was estimated using the homeostasis
model assessment for insulin resistance (HOMA-IR), which
was calculated as follows: insulin (mU/mL)6glucose (mg/
dL)/22.5618.
Metabolic syndrome was defined according to the Adult
Treatment Panel III (NCEP-ATP III) criteria of the National
Cholesterol Education Program as the presence of three or
more of the following abnormalities: waist circumference
.88 cm, fasting glucose $110 mg/dL and/or glycemia
(glucose$140 mg/dL) 120 minutes after the OGTT, fasting
serum TGs$150 mg/dL, serum HDL-c,50 mg/dL and
blood pressure$130/85 mmHg (12). High blood pressure
was defined as values$135/85 mmHg.
& METHODS
Glucose, lipid and lipoprotein levels were measured in
plasma. For the hormone assays, blood samples were
processed by centrifugation, and the serum was stored at -
20 C˚ until the assay. Progesterone, testosterone, androstene-
dione, insulin, LH and FSH were measured by an immuno-
fluorometric assay (Wallac, Finland), and DHEAS levels were
measured by a radioimmunoassay (Cisbio International,
France and DSL, TX, USA). SHBG levels were measured by
immunofluorometric assay. All the assays were performed in
duplicate, and the intra-assay and inter-assay coefficients of
variation did not exceed 10% and 15%, respectively.
Genetic analysis
DNA samples were obtained from peripheral blood
leukocytes by salting-out procedures. PCR amplification of
the GR gene regions was performed using the primer
sequences and amplification conditions described pre-
viously (13,14).
The A3669G polymorphism is located in the 39 untranslated
region of exon 9b at nucleotide position 3669 (an A-to-G
alteration), and this polymorphism was genotyped by sequen-
cing. PCR products were sequenced using the BigDye
Terminator Sequencing KitTM (Applied Biosystems, Inc.,
Foster City, CA, USA), and capillary electrophoresis was
performed using an ABI PRISM 3100 sequencer (Applied
Biosystems, Inc.).
The ER22/23EK polymorphism comprises two linked
single-nucleotide variations that are separated by one base
pair in exon 2. The first substitution at nucleotide position
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198 is silent, changing codon 22 from GAG to GAA. The
second mutation changes codon 23 at nucleotide position
200 from AGG to AAG. The N363S polymorphism changes
codon 363 of exon 2 at nucleotide position 1220 from AAT to
AGT. Sequence traces were analyzed using Sequencher
(version 4.5, build 1416).
The BclI polymorphism results in an intronic change (C to
G) that occurs 646 nucleotides downstream from exon 2.
This polymorphism was screened using allele-specific PCR,
as previously described (14). The results of the allele-specific
PCR were confirmed by direct sequencing in 20 patients.
Statistical analysis
Categorical or ordinal variables were represented as
proportions and compared using the Chi-squared test.
Continuous variables were tested for normality using the
Shapiro-Wilk test with subsequent observation of the histo-
grams to determine the distribution of the data. The normally
distributed data are represented as means with standard
deviations and compared using a Student’s t test; non-
parametric data are represented as the median and compared
using the Mann-Whitney test. Multivariate analysis was
performed using a logistic regression model for categorical
variables. P,0.05 indicated a significant difference.
Hardy-Weinberg equilibrium was calculated for the BclI
and A3669G variants. Statistical analysis was performed
using SigmaStat software (version 3.5 for Windows; Systat
Software, Point Richmond, CA).
& RESULTS
Clinical profile of the PCOS patients
The clinical, hormonal and anthropometric data of the
PCOS patients are described in Table 1. Obesity was
observed in 41 patients (42.3%), and 26 patients were
overweight (26.8%). Hypertension was observed in 17
patients (17.5%, Table 1). Metabolic syndrome, increased
TG levels ($150 mg/dL) and low HDL-c levels were
observed in 26 (26.8%), 22 (22.7%) and 51 patients (52.6%
of cases), respectively.
Decreased serum HDL-c levels were the most frequent
component of metabolic syndrome (52.6%), followed by an
increased waist circumference (47.4%), high serum TG
levels (22.7%), high blood pressure (17.5%) and high fasting
plasma glucose levels (4.1%). As expected, the frequencies
of the metabolic syndrome components were higher in the
obese patients compared with the non-obese patients (data
not shown, p,0.05), independent of androgen levels.
Influence of GR polymorphisms on the metabolic
profile of the PCOS patients
The allelic frequencies of the BclI and A3669G NR3C1
polymorphisms were in Hardy-Weinberg equilibrium. The
BclI polymorphism was found in 24.7% of the alleles: eight
homozygous patients and 32 heterozygous patients. The
A3669G polymorphism was found in 13.4% of the alleles:
two homozygous patients and 22 heterozygous patients.
The N363S and ER22/23EK alleles were identified in one
patient who was heterozygous for each polymorphism.
Considering that these alleles were present at a lower
frequency and that few patients were homozygous, we
considered the homozygous and heterozygous patients as a
single group of patients defined as ‘carriers’. For association
analysis, we selected only polymorphisms with a frequency
$10% (BclI and A3669G). Comparisons of clinical, hormonal
and laboratory data between carriers and non-carriers of the
BclI polymorphism are shown in Table 2.
Table 1 - Clinical, laboratory and anthropometric characteristics of the 97 patients with polycystic ovary syndrome.
Variables Patients with polycystic ovary syndrome
Age, mean [SD], years 24.9 (5.1)
Menstrual pattern, n (%)




BMI, mean [SD], kg/m2 29.6 (6.9)
Waist circumference, mean [SD], cm 90.1 (15.2)
Fasting glucose, mean [SD], mg/dL 89.1 (10.3)
Insulin, mean [SD], mU/L 16.6 (12.7)
HOMA-IR index, mean [SD] 3.8 (3.3)
Total cholesterol, mean [SD], mg/dL 171 (31.6)
HDL-c, mean [SD], mg/dL 50.4 (14.1)
LDL-c, mean [SD], mg/dL 98.6 (26.1)
Triglycerides, mean [SD], mg/dL 115.2 (62.1)
Obesity, n (%) 41 (42.3)
Hypertension, n (%) 17 (17.5)
Diabetes, n (%) 4 (4.1)
Metabolic syndrome, n (%) 26 (26.8)
Acne, n (%) 47 (48.5)
Insulin resistance, n (%) 50 (51.5)
Testosterone, mean [SD], ng/dL 93.4 (39.4)
Free testosterone, mean [SD], pmol/L 68.4 (39.9)
SHBG, mean [SD], nmol/L 34.3 (19)
Androstenedione, mean [SD], ng/mL 3.8 (1.4)
Ferriman-Gallwey score, mean [SD] 12.5 (6.3)
BclI carriers, n (%) 40 (41.2)
A3669G carriers, n (%) 24 (24.7)
BMI, body mass index.
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There were no significant differences observed in BMI
values; lipid, glucose and insulin levels; mFG scores; or
MetS frequencies between carriers and non-carriers of the
BclI polymorphism (Table 2). BclI carriers presented a lower
frequency of insulin resistance (IR) compared with the non-
carrier subjects (30% vs. 61.4%, p= 0.03; Table 2). There were
no significant differences in the frequencies of the BclI
polymorphism between the obese and non-obese patients
(31.7% and 48.2%, respectively) or between patients with
and without metabolic syndrome (30.8% and 45.1%,
respectively).
Table 3 shows the clinical and laboratory data of A3669G
and wild-type carriers. No differences were identified in
cardiovascular risk factors such as BMI, waist circumfer-
ence, blood pressure, HOMA-IR and IR, and differences
were not found between the hormonal and lipid profiles. No
significant differences were found in the frequencies of the
A3669G polymorphism between the obese and non-obese
patients (34.1% vs. 17.9%, respectively) or between patients
with and without metabolic syndrome (26.9% vs. 23.9%,
respectively).
The presence of NR3C1 polymorphisms was not asso-
ciated with either androgen (testosterone, DHEA and
DHEAS) or gonadotropin (LH and FSH) levels or with
menstrual cycle patterns (data not shown).
& DISCUSSION
In this study, we investigated the influence of several GR
polymorphisms on the metabolic profile of PCOS patients
and found that the BclI variant is associated with lower IR in
PCOS patients.
As expected, several features of metabolic syndrome,
including IR, obesity and dyslipidemia, were present in
PCOS patients, suggesting an increased risk of cardiovas-
cular disease in this group of patients (15).
Table 2 - Influence of the BclI polymorphism on the clinical, hormonal and metabolic profiles of patients with polycystic
ovary syndrome.
Variable BclI (N = 40) Wild-type (N=57) p-value
BMI, mean [SD], kg/m2 28.5 (6.8) 30.5 (7) 0.160
Waist circumference, mean [SD], cm 87.6 (14.5) 91.7 (15.6) 0.225
Obesity, n, (%) 13 (31.7) 28 (68.3) 0.155
Hypertension, n, (%) 6 (35.3) 11 (64.7) 0.782
Metabolic syndrome, n, (%) 8 (30.8) 18 (69.2) 0.301
Insulin resistance, n, (%) 15 (30) 35 (70) 0.035
Fasting glucose, mean [SD], mg/dL 88.7 (9.9) 89.4 (10.7) 0.733
Insulin, mean [SD], mU/L 13.3 (9.2) 18.8 (14.3) 0.06
HOMA-IR index, mean [SD] 2.98 (2.19) 4.35 (3.68) 0.076
Total cholesterol, mean [SD], mg/dL 176 (32.2) 167.4 (30.9) 0.192
HDL-c, mean [SD], mg/dL 53 (15.5) 48.6 (13) 0.193
LDL-c, mean [SD], mg/dL 102 (26.3) 96.4 (26) 0.312
Triglycerides, mean [SD], mg/dL 108 (47.7) 120 (70.5) 0.748
Testosterone, mean [SD], ng/dL 94.5 (33.4) 92.7 (43.6) 0.821
SHBG, mean [SD], nmol/L 32.7 (16.4) 35.6 (20.9) 0.761
DHEAS, mean [SD], ng/dL 2,518 (1140) 2,276 (1208) 0.332
Androstenedione, mean [SD], ng/mL 4.1 (1.4) 3.7 (1.5) 0.231
Ferriman-Gallwey score, mean [SD] 11.9 (6.5) 12.9 (6.3) 0.423
BMI: body mass index.
Table 3 - Influence of the A3669G polymorphism on the clinical, hormonal and metabolic profiles of patients with
polycystic ovary syndrome.
Variable A3669G (N=24) Wild-type (N=73) p-value
BMI, mean [SD], kg/m2 31.9 (6.9) 28.9 (6.9) 0.071
Waist circumference, mean [SD], cm 91.5 (15.9) 89.6 (15.1) 0.618
Obesity, n, (%) 14 (34.1) 27 (65.9) 0.110
Hypertension, n, (%) 5 (29.4) 12 (70.6) 0.856
Metabolic syndrome, n, (%) 7 (26.9) 19 (73.1) 0.972
Insulin resistance, n, (%) 15 (30) 35 (70) 0.316
Fasting glucose, mean [SD], mg/dL 88.9 (12.5) 89.1 (9.6) 0.794
Insulin, mean [SD], mU/L 19.1 (14.7) 15.9 (12.1) 0.401
HOMA-IR index, mean [SD] 4.5 (3.6) 3.6 (3.1) 0.338
Total cholesterol, mean [SD], mg/dL 173.7 (29.4) 170.1 (32.4) 0.631
HDL-c, mean [SD], mg/dL 48.2 (12.4) 51.1 (14.7) 0.532
LDL-c, mean [SD], mg/dL 99.7 (30.3) 98.3 (24.8) 0.829
Triglycerides, mean [SD], mg/dL 124.7 (69.3) 112.1 (59.7) 0.543
Testosterone, mean [SD], ng/dL 96 (40.7) 92.7 (39.3) 0.730
SHBG, mean [SD], nmol/L 28.2 (12.1) 36.5 (20.6) 0.170
DHEAS, mean [SD], ng/dL 2,408 (1,227) 2,362 (1,174) 0.874
Androstenedione, mean [SD], ng/mL 4.2 (1.8) 3.7 (1.3) 0.209
Ferriman-Gallwey score, mean [SD] 12.8 (5.5) 12.4 (6.6) 0.882
BMI, body mass index.
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In addition to the aforementioned factors, familial and/or
genetic predisposition may be involved in the increased
cardiovascular risk in PCOS patients. The influence of
genetic polymorphisms on the metabolic profile of PCOS
patients has been studied, and positive associations have
been found with lipid profiles (16), insulin and homocys-
teine levels (17,18), high body weight and abdominal
adiposity (19).
The influence of NR3C1 polymorphisms on cardiovascu-
lar risk in the general population has been analyzed, and
several are associated with changes in GC sensitivity, which
influence the metabolic profile of their carriers (2-4,20-23). In
PCOS patients, two studies have investigated the associa-
tion between NR3C1 polymorphisms and hormonal profiles.
The first study evaluated a rare NR3C1 gene allele, N363S,
and its impact on the frequency of androgen excess.
However, this polymorphism was found in only 3.3% of
patients, and no significant difference was found between
the frequencies of PCOS patients with and without andro-
gen excess (24). The second study found a positive
association between the A3669G and ER22/23EK poly-
morphisms, which decrease GC sensitivity, and changes in
luteinizing hormone levels (25). For the first time, we have
analyzed the impact of NR3C1 polymorphisms on the
metabolic profile of PCOS patients.
GC actions are mediated through the functional isoform
of the GR, GR-a. An alternative isoform, GR-b, behaves as a
dominant negative inhibitor of GR-a and is implicated in
GC resistance. The A3669G polymorphism, located in exon
9b, increases GR-b protein expression, resulting in greater
inhibition of GR-a and a subsequent increase in relative GC
resistance. This carrier status could result in a phenotype
that protects against the undesirable effects of GCs on fat
distribution and glucose metabolism (2). However, we did
not identify any differences between the metabolic profiles
of carriers and non-carriers.
The BclI restriction fragment length polymorphism has
been linked to a cluster of cardiovascular risk factors in
men, including hypertension, obesity and IR (4,5,20).
However, these associations were not found in our study.
In contrast to what has been described in the literature, we
found a positive association between the BclI variant and
lower IR (Table 2), which may be due to the fact that our
study group was exclusively composed of women. Indeed,
gender-specific effects of NR3C1 gene polymorphisms on
anthropometric and metabolic variables have been observed
in several studies (2,23,26,27). For example, in a recent
study, NR3C1 polymorphisms were associated with
reduced first-phase glucose-stimulated insulin secretion
and the disposition index in women, but not in men (28).
Additionally, gender-related hormonal factors are known to
affect b-cell function, as women receiving estrogen replace-
ment therapy display a reduced prevalence of diabetes,
which has been associated with the b-cell-protective effects
of estrogens (29). Furthermore, the male sex hormone
testosterone may also affect b-cell function (30). Therefore,
it has been speculated that NR3C1 gene polymorphisms
could interact differently with sex hormones to affect b-cell
function and consequently present different phenotypes.
The main weakness of our study is the small number of
PCOS patients analyzed, which prevented us from drawing
definite conclusions about the relationship between NR3C1
polymorphisms and other clinical features; however, the
findings of our study suggest that the BclI and A3669G
polymorphisms may play a protective role. Multicentric
studies are needed to further explore these early findings.
In conclusion, this is the first report revealing the
influence of the BclI and A3669G polymorphisms on the
metabolic profile of PCOS patients. In the future, poly-
morphism screening during PCOS treatment may poten-
tially be used to improve the quality of treatment by
identifying subgroups of at-risk patients who would benefit
the most from personalized treatment.
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